A Phase II Study Of Intravenous T900607-Sodium In Subjects With Previously Treated Gastric Carcinoma
- Determine the response rate (complete and partial) in patients with previously treated
gastric or gastroesophageal junction carcinoma treated with T900607. (Gastric carcinoma
closed to accrual as of 02/04.)
- Determine the duration of response and time to disease progression in patients treated
with this drug.
- Determine the pharmacokinetics of this drug in these patients.
- Determine the safety profile of this drug in these patients.
OUTLINE: This is an open-label, multicenter study.
Patients receive T900607 IV over 1 hour once weekly. Treatment continues in the absence of
disease progression or unacceptable toxicity.
Patients are followed every 3 months.
PROJECTED ACCRUAL: A total of 20-35 patients will be accrued for this study.
Masking: Open Label, Primary Purpose: Treatment
Joanna M. Brell, MD
Case Comprehensive Cancer Center
United States: Federal Government
|Ireland Cancer Center||Cleveland, Ohio 44106-5065|